» Articles » PMID: 34065316

Risk Categories in COVID-19 Based on Degrees of Inflammation: Data on More Than 17,000 Patients from the Spanish SEMI-COVID-19 Registry

Abstract

(1) Background: The inflammation or cytokine storm that accompanies COVID-19 marks the prognosis. This study aimed to identify three risk categories based on inflammatory parameters on admission. (2) Methods: Retrospective cohort study of patients diagnosed with COVID-19, collected and followed-up from 1 March to 31 July 2020, from the nationwide Spanish SEMI-COVID-19 Registry. The three categories of low, intermediate, and high risk were determined by taking into consideration the terciles of the total lymphocyte count and the values of C-reactive protein, lactate dehydrogenase, ferritin, and D-dimer taken at the time of admission. (3) Results: A total of 17,122 patients were included in the study. The high-risk group was older (57.9 vs. 64.2 vs. 70.4 years; < 0.001) and predominantly male (37.5% vs. 46.9% vs. 60.1%; < 0.001). They had a higher degree of dependence in daily tasks prior to admission (moderate-severe dependency in 10.8% vs. 14.1% vs. 17%; < 0.001), arterial hypertension (36.9% vs. 45.2% vs. 52.8%; < 0.001), dyslipidemia (28.4% vs. 37% vs. 40.6%; < 0.001), diabetes mellitus (11.9% vs. 17.1% vs. 20.5%; < 0.001), ischemic heart disease (3.7% vs. 6.5% vs. 8.4%; < 0.001), heart failure (3.4% vs. 5.2% vs. 7.6%; < 0.001), liver disease (1.1% vs. 3% vs. 3.9%; = 0.002), chronic renal failure (2.3% vs. 3.6% vs. 6.7%; < 0.001), cancer (6.5% vs. 7.2% vs. 11.1%; < 0.001), and chronic obstructive pulmonary disease (5.7% vs. 5.4% vs. 7.1%; < 0.001). They presented more frequently with fever, dyspnea, and vomiting. These patients more frequently required high flow nasal cannula (3.1% vs. 4.4% vs. 9.7%; < 0.001), non-invasive mechanical ventilation (0.9% vs. 3% vs. 6.3%; < 0.001), invasive mechanical ventilation (0.6% vs. 2.7% vs. 8.7%; < 0.001), and ICU admission (0.9% vs. 3.6% vs. 10.6%; < 0.001), and had a higher percentage of in-hospital mortality (2.3% vs. 6.2% vs. 23.9%; < 0.001). The three risk categories proved to be an independent risk factor in multivariate analyses. (4) Conclusion: The present study identifies three risk categories for the requirement of high flow nasal cannula, mechanical ventilation, ICU admission, and in-hospital mortality based on lymphopenia and inflammatory parameters.

Citing Articles

Should the Start of Immunosuppressive Treatment for COVID-19 Rely upon the Degree of Inflammation or the Time from Onset?.

Mora-Lujan J, Montero A, Formiga F, Rubio-Rivas M Medicina (Kaunas). 2025; 61(2).

PMID: 40005350 PMC: 11857332. DOI: 10.3390/medicina61020233.


Analyzing prognosis and comparing predictive scoring systems for mortality of COVID-19 patients with liver cirrhosis: a multicenter retrospective study.

Chen S, Ng C, Huang Y, Lo H BMC Infect Dis. 2024; 24(1):1315.

PMID: 39558236 PMC: 11572522. DOI: 10.1186/s12879-024-10223-4.


Methodological biases in observational hospital studies of COVID-19 treatment effectiveness: pitfalls and potential.

Martinuka O, Hazard D, Marateb H, Mansourian M, Mananas M, Romero S Front Med (Lausanne). 2024; 11:1362192.

PMID: 38576716 PMC: 10991758. DOI: 10.3389/fmed.2024.1362192.


Risk of COVID-19 death for people with a pre-existing cancer diagnosis prior to COVID-19-vaccination: A systematic review and meta-analysis.

Steinberg J, Hughes S, Hui H, Allsop M, Egger S, David M Int J Cancer. 2023; 154(8):1394-1412.

PMID: 38083979 PMC: 10922788. DOI: 10.1002/ijc.34798.


Mortality reduction in older COVID-19-patients hospitalized in Spain during the second pandemic wave from the SEMI-COVID-19 Registry.

Casas-Rojo J, Anton-Santos J, Millan-Nunez-Cortes J, Gomez-Huelgas R, Ramos-Rincon J, Rubio-Rivas M Sci Rep. 2023; 13(1):17731.

PMID: 37853011 PMC: 10584827. DOI: 10.1038/s41598-023-42735-5.


References
1.
Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

2.
Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A . Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; 323(16):1574-1581. PMC: 7136855. DOI: 10.1001/jama.2020.5394. View

3.
Salvarani C, Dolci G, Massari M, Merlo D, Cavuto S, Savoldi L . Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2020; 181(1):24-31. PMC: 7577199. DOI: 10.1001/jamainternmed.2020.6615. View

4.
Perez-Belmonte L, Torres-Pena J, Lopez-Carmona M, Ayala-Gutierrez M, Fuentes-Jimenez F, Jorge Huerta L . Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study. BMC Med. 2020; 18(1):359. PMC: 7666969. DOI: 10.1186/s12916-020-01832-2. View

5.
Rodilla E, Lopez-Carmona M, Cortes X, Cobos-Palacios L, Canales S, Saez M . Impact of Arterial Stiffness on All-Cause Mortality in Patients Hospitalized With COVID-19 in Spain. Hypertension. 2020; 77(3):856-867. PMC: 7884247. DOI: 10.1161/HYPERTENSIONAHA.120.16563. View